FLT3 and acute myeloid leukemia: A small phase II trial in de novo FLT3 AML in patients 60 or younger examined 7 + 3 induction chemotherapy plus crenolanib, and consolidation chemotherapy followed by either HSCT or maintenance crenolanib therapy.